CTLA4 and cancer: In the past decade, the development of immune checkpoint inhibitors (ICPIs) such as PD-1/PD-L1 and CTLA-4 inhibitors provided a breakthrough in the cancer therapies as evident by the increasing FDA approvals in recent years.